841 BC556, A POTENT, PAN-GENOTYPIC, HIGH BARRIER TO RESISTANCE, SECOND GENERATION CYCLOPHILIN INHIBITOR FOR TREATMENT OF CHRONIC HCV INFECTIONSteven J. Moss, Matthew A. Gregory, Timothy P. Foster et al.|Journal of Hepatology|2012Cited by 2
789 PRECLINICAL CHARACTERIZATION OF NOVEL CYCLOPHILIN INHIBITORS BASED ON THE POLYKETIDE, SANGLIFEHRINSteven J. Moss, Matthew A. Gregory, Michael Bobardt et al.|Journal of Hepatology|2011Cited by 0